Literature DB >> 11877256

Myeloid cell factor-1 is a critical survival factor for multiple myeloma.

Bin Zhang1, Ivana Gojo, Robert G Fenton.   

Abstract

Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells in the bone marrow caused primarily by failure of normal homeostatic mechanisms to prevent the expansion of postgerminal center plasma cells. We have examined the molecular mechanisms that promote the survival of MM cells and have identified a key role for myeloid cell factor-1 (Mcl-1), an antiapoptotic member of the Bcl-2 family. These experiments were initiated by the observation that MM cells were exquisitely sensitive to culture in the presence of actinomycin D: caspase activation occurred within 3 hours of treatment and cells were not protected by interleukin-6, the main MM cell growth and survival factor. Actinomycin D-induced apoptosis was blocked by proteasome inhibitors, suggesting that a labile protein was required for MM cell survival. Further analysis demonstrated that Mcl-1 was likely to be the labile factor governing MM cell survival. Mcl-1 protein levels decreased rapidly after culture in the presence of actinomycin D in concordance with effector caspase activation, but addition of proteasome inhibitors reversed the loss of Mcl-1 and maintained cell viability. The levels of other antiapoptotic proteins, including Bcl-2 and members of the inhibitors-of-apoptosis family, were unaffected by these interventions. Furthermore, Mcl-1 antisense oligonucleotides caused a rapid down-regulation of Mcl-1 protein levels and the coincident induction of apoptosis, whereas overexpression of Mcl-1 delayed actinomycin D-induced apoptosis with kinetics that correlated with expression levels of Mcl-1. These data indicate that Mcl-1 expression is required for the survival of MM cells and may represent an important target for future therapeutics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11877256     DOI: 10.1182/blood.v99.6.1885

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  126 in total

1.  Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.

Authors:  Rodger E Tiedemann; Yuan Xao Zhu; Jessica Schmidt; Chang Xin Shi; Chris Sereduk; Hongwei Yin; Spyro Mousses; A Keith Stewart
Journal:  Cancer Res       Date:  2011-12-06       Impact factor: 12.701

2.  Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation.

Authors:  Deepak Nijhawan; Min Fang; Elie Traer; Qing Zhong; Wenhua Gao; Fenghe Du; Xiaodong Wang
Journal:  Genes Dev       Date:  2003-06-03       Impact factor: 11.361

3.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

Authors:  Mark F van Delft; Andrew H Wei; Kylie D Mason; Cassandra J Vandenberg; Lin Chen; Peter E Czabotar; Simon N Willis; Clare L Scott; Catherine L Day; Suzanne Cory; Jerry M Adams; Andrew W Roberts; David C S Huang
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

4.  Structural insights into the degradation of Mcl-1 induced by BH3 domains.

Authors:  Peter E Czabotar; Erinna F Lee; Mark F van Delft; Catherine L Day; Brian J Smith; David C S Huang; W Douglas Fairlie; Mark G Hinds; Peter M Colman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-27       Impact factor: 11.205

5.  Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.

Authors:  Michel Jourdan; Thierry Reme; Hartmut Goldschmidt; Geneviève Fiol; Véronique Pantesco; John De Vos; Jean-François Rossi; Dirk Hose; Bernard Klein
Journal:  Br J Haematol       Date:  2009-01-08       Impact factor: 6.998

6.  BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines.

Authors:  Sarah T Diepstraten; Catherine Chang; Lin Tai; Jia-Nan Gong; Ping Lan; Alexander C Dowell; Graham S Taylor; Andreas Strasser; Gemma L Kelly
Journal:  Blood Adv       Date:  2020-01-28

Review 7.  Global gene expression profiling in the study of multiple myeloma.

Authors:  John D Shaughnessy
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

Review 8.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

9.  BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Authors:  Jérôme Moreaux; Eric Legouffe; Eric Jourdan; Philippe Quittet; Thierry Rème; Cécile Lugagne; Philippe Moine; Jean-François Rossi; Bernard Klein; Karin Tarte
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

Review 10.  The Tao of myeloma.

Authors:  Lawrence H Boise; Jonathan L Kaufman; Nizar J Bahlis; Sagar Lonial; Kelvin P Lee
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.